home / stock / oxbdf / oxbdf quote
Last: | $4.445 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $4.445 |
High: | $0 |
Low: | $0 |
Volume: | 26 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.445 | $0 | $4.445 | $0 | $0 | 26 | 07-18-2024 |
$4.445 | $4.445 | $4.445 | $4.445 | $4.445 | 250 | 07-17-2024 |
$4.435 | $0 | $4.435 | $0 | $0 | 50 | 07-16-2024 |
$4.435 | $0 | $4.435 | $0 | $0 | 90 | 07-12-2024 |
$4.435 | $4.435 | $4.435 | $4.435 | $4.435 | 150 | 07-10-2024 |
$3.72 | $0 | $3.72 | $0 | $0 | 5 | 07-08-2024 |
$3.72 | $0 | $3.72 | $0 | $0 | 153 | 07-05-2024 |
$3.72 | $0 | $3.72 | $0 | $0 | 31 | 07-02-2024 |
$3.72 | $3.72 | $3.72 | $3.72 | $3.72 | 391 | 06-27-2024 |
$3.97 | $0 | $3.97 | $0 | $0 | 20 | 06-26-2024 |
$3.97 | $3.97 | $3.97 | $3.97 | $3.97 | 200 | 06-25-2024 |
$4.1 | $0 | $4.1 | $0 | $0 | 91 | 06-21-2024 |
$4.1 | $4.1 | $4.1 | $4.1 | $4.1 | 1,000 | 06-14-2024 |
$4.31 | $0 | $4.31 | $0 | $0 | 20 | 06-12-2024 |
$4.31 | $0 | $4.31 | $0 | $0 | 80 | 06-06-2024 |
$4.31 | $4.31 | $4.31 | $4.31 | $4.31 | 2,000 | 06-04-2024 |
$4.4006 | $0 | $4.4006 | $0 | $0 | 60 | 05-29-2024 |
$4.4006 | $4.64 | $4.4006 | $4.64 | $4.4006 | 300 | 05-23-2024 |
$4.4 | $4.3 | $4.4 | $4.4 | $4.3 | 323 | 05-21-2024 |
$3.86 | $0 | $3.86 | $0 | $0 | 26 | 05-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
EXPRESS INC. DL-01 (02Z0:DU) is expected to report $-8.99 for Q4 2024 Oxford Biomedica (OXBDF) is expected to report for Q4 2023 Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q4 2024 Express (02Z0:MU) is expected to report $-8.99 for Q4 2024 Express Inc. - Ord...
Oxford Biomedica (OXBDF) is expected to report for Q4 2023
LONDON, UK / ACCESSWIRE / October 5, 2020 / Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical component of cell and gene therapies (CGTs). An investment in OXB gives a broad exposure to this emer...